3.62
-0.05 (-1.36%)
| Previous Close | 3.67 |
| Open | 3.61 |
| Volume | 89,755 |
| Avg. Volume (3M) | 237,579 |
| Market Cap | 86,696,104 |
| Price / Sales | 1.11 |
| Price / Book | 9.89 |
| 52 Weeks Range | |
| Earnings Date | 18 Aug 2025 |
| Profit Margin | -106.77% |
| Operating Margin (TTM) | -52.24% |
| Diluted EPS (TTM) | -2.64 |
| Quarterly Revenue Growth (YOY) | 49.70% |
| Quarterly Earnings Growth (YOY) | -60.90% |
| Total Debt/Equity (MRQ) | 778.95% |
| Current Ratio (MRQ) | 0.380 |
| Operating Cash Flow (TTM) | -6.40 M |
| Levered Free Cash Flow (TTM) | 10.32 M |
| Return on Assets (TTM) | -17.42% |
| Return on Equity (TTM) | -232.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Celularity Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -1.75 |
|
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 51.26% |
| % Held by Institutions | 14.66% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| C V Starr & Co Inc | 30 Jun 2025 | 764,069 |
| Valmark Advisers, Inc. | 30 Jun 2025 | 49,983 |
| Keynote Financial Services Llc | 30 Jun 2025 | 23,480 |
| 52 Weeks Range | ||
| Median | 6.00 (65.75%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| WBB Securities | 09 Sep 2025 | 6.00 (65.75%) | Buy | 2.26 |
| 18 Aug 2025 | 6.00 (65.75%) | Not Rated | 4.15 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance |
| 22 Aug 2025 | Announcement | Celularity Receives Nasdaq Notice Regarding Form 10-Q |
| 18 Aug 2025 | Announcement | Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt |
| 09 Jul 2025 | Announcement | Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law |
| 01 Jul 2025 | Announcement | Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |